Overexpression of EMMPRIN is associated with lymph node metastasis and advanced stage of non-small cell lung cancer: a retrospective study

Bing Liu,Qingdi Zeng,Yong Lin,Congcong Qi,Baowei Sheng,Zhaohui Wan,Tian Fu

doi:10.1186/s12890-017-0540-1

Abstract

BackgroundPrevious studies show that overexpression of EMMPRIN involved in the malignant biological behavior of tumors. This investigation was to disclose the expression status of EMMPRIN in non-small cell lung cancer (NSCLC) and its clinical value for the diagnosis of NSCLC.MethodsThe expression of EMMPRIN was examined using immunohistochemistry and enzyme-linked immunosorbent assay. The clinical value of EMMPRIN was evaluated by drawing a receiver operating characteristic (ROC) curve.ResultsNSCLC tissues and serum exhibited higher expression levels of EMMPRIN than the normal control (p < 0.05), and the expression of the EMMPRIN was significantly associated with lymphatic invasion and advanced stage of NSCLC (p < 0.05). ROC curve suggested that the threshold level of serum EMMPRIN for distinguishing NSCLC from control group was 80.3 pg/mL, and displayed a sensitivity of 97.22% and a specificity of 95%. And higher EMMPRIN expression in serum and tissues appeared to be risk factors for NSCLC development (risk ratio =1.56 and 1.1).ConclusionOverexpression of EMMPRIN was associated with lymphatic metastasis and advanced stage of NSCLC and test of serum EMMPRIN contributes to the NSCLC diagnosis.

Highlights

Previous studies show that overexpression of Extracellular matrix metalloproteinase inducer (EMMPRIN) involved in the malignant biological behavior of tumors
Over-expression of EMMPRIN correlated with histological type, poor differentiation, lymph node metastasis and advanced stage of non-small cell lung cancer (NSCLC) As shown in Table 2, the expression of EMMPRIN did not relate to gender, age, and smoking status of NSCLC patients (p > 0.05)
The expression level of EMMPRIN was up-regulated in lung adenocarcinoma (LAC) (16/23, 69.6%) (p = 0.034), poorly differentiated lung cancer tissues (15/17, 88.2%) (p < 0.001), NSCLC cases with N2-N3 of lymph node metastasis (23/29, 79.3%) (p < 0.001) and NSCLC tissues of stages IIIB (18/20, 90%) (p < 0.001), as compared with lung squamous cell carcinoma (LSCC) (13/32, 40.6%), well-differentiated tissues (5/25, 20%), lung cancer cases with N0-N1 of lymph node metastasis (6/26, 23.1%) and those of stages IIA-IIIA (11/35, 31.4%)

Summary

Introduction

Previous studies show that overexpression of EMMPRIN involved in the malignant biological behavior of tumors. This investigation was to disclose the expression status of EMMPRIN in non-small cell lung cancer (NSCLC) and its clinical value for the diagnosis of NSCLC. People believe that early diagnosis of lung cancer play an important role in reducing of morbidity and mortality [2]. This is a consensus that the change levels of some molecules. Recent reports have indicated that the expressions of EMMPRIN correlate with poor clinical factors and outcomes in lung cancer but some studies

Methods

Results

Discussion

Conclusion